



CAMB/IMM 6090: Vaccines & Immune Therapy Fall 2024

Time: 3:30 PM – 5:30 PM

Location: The Wistar Institute

Grossman Auditorium / Zoom

Instructors: David Weiner, Paul Offit, Stanley Plotkin, Emilio Emini

Class Coordinator: Jeneice Hubert

V-Virtual Lecture / IP – In Person Lecture

<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Sept 18	Welcome	David Weiner – Wistar IP
	Vaccine History	
Sept 19	Cellular Immune Responses	Michael Betts – PENN IP
Sept 25	Adoptive Cell Therapy for Cancer	Marco Ruella – UPENN IP
Sept 26	B Cells, Antibodies, & Humoral Immune Response	David Allman – PENN IP
Oct 2	Cure-HIV	Luis Montaner – Wistar IP
Oct 3	NO CLASS - UPENN FALL BREAK	
Oct 9	TBA	
Oct 10	Vaccine development against human Herpes viruses: Success and Challenges	Sita Awasthi – UPENN IP
Oct 16	Rotavirus Vaccines	Paul Offit – CHOP IP
	Nucleoside Modified mRNA-LNP Therapeutics	Drew Weissman – UPENN IP
Oct 17	Vaccine Safety	Paul Offit – CHOP IP
Oct 23	Correlates of Protection by Vaccines	Stanley Plotkin – Emeritus IP

JENEICE HUBERT

Weiner Lab Coordinator

Assistant to: Dr. David B. Weiner

P (215) 898-0381 E jhubert@wistar.org



<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Oct 24	Novel technologies to develop AMR vaccines & Vaccines against AMR pathogens	Sanjay Phogat – GSK IP
Oct 30	The Challenges of Vaccine Development: Technical, Financial, and Political	Emilio Emini – *RETIRED* Bill & Melinda Gates Medical Research Institute IP
Oct 31	Developing a heterologous prime-boost Ebola vaccine – challenges and opportunities	Ruxandra Draghia-Akli – *RETIRED* Janssen IP
Nov 6	The Role of antibodies in RSV prevention: The story of Nirsevimab	Tonya Villafana – AstraZeneca IP
	Passive Immunization with Suvratoxumab To Prevent S. Aureus Ventilator Associated Pneumonias	Mark Esser – AstraZeneca IP
Nov 7	Development of a COVID-19 mRNA Vaccine at Lightspeed	Kathrin Jansen *RETIRED* Pfizer IP
Nov 13	Case Studies in End-to-End Vaccine Research and Development	Annaliesa Anderson – Pfizer IP
Nov 14	Required Reading - Books Distributed Final Exam Review & Topics	Class Coordinator
Nov 20	Overview of the Advisory Committee on Immunization practices (ACIP) Example: Hepatitis A Disease and Vaccines	Michelle Goveia – Merck IP
	Developing vaccines against emerging infections outside of the usual regulatory framework	Gary Kobinger –IP Galveston National Laboratory
Nov 21	Regulatory Considerations for Preventative Vaccines	Rachel Zhang – FDA V
	Understanding Vaccine Safety After Licensure	Meghna Alimchandani – FDA V
Nov 27	NO CLASS – THANKSGIVING HOLIDAY	
Nov 28	NO CLASS – THANKSGIVING HOLIDAY	



<u>Date</u>	<u>Title</u>	<u>Lecturer</u>
Dec 4	Developing a SARS CoV-2 Vaccine at Warp Speed	Paul Offit – CHOP IP
	Vaccines for Infectious Diseases that Disproportionately Impact the Poor	Penny Heaton – Janssen IP
Dec 5	Building Trust to Achieve Vaccine Confidence	Rodney Finalle – Merck IP
	Cancer Vaccines	Matthew Morrow – Inovio IP
Dec 11	Meningococcal Vaccines	Sarah Schillie – CDC V
	Preventing Dengue at Last: The Complex Quest for a Dengue Vaccine	German Anez – Merck IP
Dec 12	NO CLASS	
Dec 18 & 19	Final Exam Event	Course Examiners

Virtual Link:

CAMB-IMM 6090 Vaccines & Immune Therapy Course

Join Zoom Meeting

<https://us02web.zoom.us/j/85945679996?pwd=W3NRKza19058zHdcFePELT50CH4rXv.1>

JENEICE HUBERT

Weiner Lab Coordinator

Assistant to: Dr. David B. Weiner

P (215) 898-0381 E jhubert@wistar.org